(3R)-3-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-1-(2-oxo-2-phenylethyl)-1-azoniabicyclo[2.2.2]octane bromide | 1198175-26-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R)-3-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-1-(2-oxo-2-phenylethyl)-1-azoniabicyclo[2.2.2]octane bromide
• 英文别名: [(3R)-1-phenacyl-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide
• CAS: 1198175-26-6
• 化学式: Br*C₂₅H₂₆NO₄S₂
• 分子量: 548.522
• InChiKey: OCMLOCNJXIVNAP-IXKBQBJRSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.08
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Muscarinic receptor antagonists
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2130830A1

  公开（公告）日：2009-12-09

  The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and the method for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical composition comprising one or more muscarinic receptor antagonists and at least one other active ingredients include, but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors.

  本发明一般涉及肌碱受体拮抗剂，这些拮抗剂可用于治疗通过肌碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病，除其他用途外。该发明还涉及所述化合物的制备过程、含有所述化合物的药物组合物以及治疗通过肌碱受体介导的疾病的方法。本文还提供了含有一种或多种肌碱受体拮抗剂和至少一种其他活性成分的药物组合物，包括但不限于皮质类固醇、β-激动剂、白三烯拮抗剂、5-脂氧合酶抑制剂、抗组胺药、止咳药、多巴胺受体拮抗剂、趋化因子抑制剂、p38 MAP激酶抑制剂和PDE-IV抑制剂。
• MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：KUMAR Naresh

  公开号：US20090326004A1

  公开（公告）日：2009-12-31

  The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and the method for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical composition comprising one or more muscarinic receptor antagonists and at least one other active ingredients include, but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors.

  本发明涉及一般用于治疗通过毒蕈碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病的毒蕈碱受体拮抗剂。该发明还涉及所述化合物的制备过程、含有所述化合物的药物组合物以及治疗通过毒蕈碱受体介导的疾病的方法。本文还提供了包含一种或多种毒蕈碱受体拮抗剂和至少一种其他活性成分的药物组合物，包括但不限于皮质类固醇、β-激动剂、白三烯拮抗剂、5-脂氧合酶抑制剂、抗组胺药、止咳药、多巴胺受体拮抗剂、趋化因子抑制剂、p38 MAP 激酶抑制剂和 PDE-IV 抑制剂。